Denali Therapeutics Current Deferred Revenue Over Time
| DNLI Stock | USD 25.16 0.48 1.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Denali Therapeutics Performance and Denali Therapeutics Correlation. Denali |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Denali Therapeutics and related stocks such as Homology Medicines, Stoke Therapeutics, and Atreca Inc Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOK | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | 12.7 M | 14.9 M | 15.3 M | 11.5 M |
| FDMT | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.4 M | 4.9 M | 5.9 M | 6.6 M | 2.6 M | 884 K | 273 K | 259.4 K |
| ASND | 19.7 M | 19.7 M | 21.1 M | 17.5 M | 7.9 M | 3.1 M | 94 K | 6.9 M | 6.9 M | 858 K | 363 K | 2.6 M | 1.2 M | 1.1 M | 1 M |
| APLS | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 111.9 M | 103.2 M | 103.2 M | 92.9 M | 86.1 M |
| BGNE | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 8.9 M | 1.1 M | 12.2 M | 12.2 M | 18.1 M | 366.5 M | 366.5 M | 407.7 M | 255.9 M | 300 K | 285 K |
| BPMC | 1 M | 1 M | 1 M | 1 M | 3.9 M | 5.9 M | 11.4 M | 5.4 M | 3.6 M | 6.2 M | 12.6 M | 36.6 M | 448.6 M | 812 K | 771.4 K |
| LEGN | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 40.3 M | 46.3 M | 55.3 M | 60.9 M | 451 K | 53 M | 45 M |
| PCVX | (297 K) | (297 K) | (297 K) | (297 K) | (297 K) | (297 K) | (297 K) | (297 K) | (297 K) | (119.7 M) | (119.7 M) | (119.7 M) | (119.7 M) | (107.7 M) | (102.3 M) |
| TVTX | 2.5 M | 2.5 M | 2.5 M | 28.9 M | 28.9 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | (2.6 M) | (357 K) | 16.3 M | 12 M | 7.1 M | 11.3 M |
| RNA | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.7 M | 4.9 M | 5 M | 28.4 M | 29.8 M |
| RVMD | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 17.1 M | 20.6 M | 18.9 M | 4.5 M | (54.6 M) | (51.8 M) |
| DAWN | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 6.6 M | 25.5 M | 29.3 M | 30.8 M |
| SWTX | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 363 K | 3.3 M | 3.3 M | 3.3 M | 4.1 M | 2.9 M |
| GLUE | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 15.9 M | 14.1 M |
| DSGN | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 180.9 K | 160.8 K |
| HOWL | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 907 K | 861.6 K |
| IKNA | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 20.6 M | 17.1 M | 9.2 M | 1.0 | 0.95 |
Denali Therapeutics and related stocks such as Homology Medicines, Stoke Therapeutics, and Atreca Inc Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Denali Therapeutics | DNLI |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 25.16
Check out Denali Therapeutics Performance and Denali Therapeutics Correlation. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Denali Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.